Chapter 195- Antiangiogenic Agents

Question 1

Act directly on untransformed endothelial cells to prevent proliferation, migration, and survival

Answer 1

Direct antiangiogenic agents

Question 2

Inhibit tumor-produced oncogene proteins that promote a proangiogenic state

Answer 2

Indirect antiangiogenic agents

Question 3

First FDA- approved angiogenesis-stimulating therapy

Answer 3

Becaplermin (recombinant human platelet-derived growth factor BB)

Question 4

Important factor in formation of granulation tissue

Answer 4

PDGF

Question 5

Becaplermin is indicated for treatment of diabetic, neuropathic ulcers that are (2)

Answer 5

Well-vascularized; reach the level of the subQ tissue

Question 6

Becaplermin is contraindicated in

Answer 6

Sites of previous malignancy, allergy

Question 7

Safety and efficacy of becaplermin has not been evaluated in children ages

Answer 7

16 or lower

Question 8

Matching type
1. Becaplermin

A. A
B. B
C. C
D. D
E. E

Answer 8

C

Question 9

Recombinant humanized IgG1 monoclonal antibody against VEGF1 and VEGF2

Answer 9

Bevacizumab

Question 10

Detrimental prognostic factor in patients with colorectal cancer treated with chemotherapy plus bevacizumab

Answer 10

Notch 1 hyperexpression

Question 11

First FDA approved antiangiogenic drug for treatment of metastatic colorectal carcinoma with IV 5 FU based chemotherapy

Answer 11

Bevacizumab (Avastatin)

Question 12

Complications of Bevacizumab (8)

Answer 12

GI perforation
Wound dehiscence
Serious hemorrhage
Arterial thromboembolic events
Reversible posterior leukoencephalopathy
HPN
Proteinuria
Infusion reactions

Question 13

Neurologic disorder characterized by headache, seizures, lethargy, confusion, blindness

Answer 13

Reversible posterior leukoencephalopathy syndrome

Question 14

Promotes a proaptotic state by preventing degradation of tumor suppressor proteins (p53, NFKB inhibitors)

Answer 14

Proteosome inhibitor

Question 15

Indicated for treatment of multiple myeloma and mantle cell lymphoma

Answer 15

Bortezomib

Question 16

Chimeric human-murine monoclonal antibody against EGFR

Answer 16

Cetuximab

Question 17

Indicated for the treatment for metastatic colorectal carcinoma and squamous cell carcinoma of head and neck

Answer 17

Cetuximab (Erbitux)

Question 18

Complications of Cetuximab

Answer 18

Acneiform neutrophilic folliculitis

Serious infection reactions